Glioblastoma Treatment 2026–2030: Targets, Modalities, and Pipeline Overview
TL;DR
- Neurosurgeon and VC investor Luis Pareras MD PhD reviews the full GBM treatment pipeline through 2030.
- Five treatment categories covered: small molecules, biologics, gene and oncolytic virus therapies, cell therapies, and combination/delivery approaches.
- Includes eight comparison tables and an efficacy scorecard across all major modalities.
Read the full article by Luis Pareras MD PhD →
Overview
Glioblastoma (GBM) remains one of the most treatment-resistant cancers known to medicine. Median survival after diagnosis is 12 to 15 months. Fewer than 1 in 10 patients survive five years. Despite decades of research, outcomes have improved only marginally since the early 2000s.
The article above was written by Luis Pareras MD PhD, a neurosurgeon and venture capital investor. It represents his perspective on the current glioblastoma treatment landscape and pipeline through 2030, written primarily for an investor and research audience. It is not a clinical guideline and does not constitute medical advice. Readers should consult their medical team regarding treatment decisions.
What the article covers
The article is organized around five treatment categories:
Small molecule drugs — kinase inhibitors, PI3K/mTOR inhibitors, and cell cycle modulators. Clinical trial results are reviewed for regorafenib, paxalisib, osimertinib, abemaciclib, and others.
Biologics — monoclonal antibodies, antibody-drug conjugates, bispecific T cell engagers, and cytokine therapies. Covers bevacizumab, checkpoint inhibitors, Depatux-M, AMG 596, and the Ad-RTS-hIL-12 regulated cytokine approach.
Gene and oncolytic virus therapies — including G47Δ (conditionally approved in Japan in 2021 for recurrent or residual GBM), DNX-2401, PVSRIPO, and mRNA vaccine approaches.
Cell therapies — autologous and allogeneic CAR-T cells, CAR-NK cells, TCR-engineered T cells, dendritic cell vaccines, and macrophage-based approaches. Covers trials from City of Hope, UPenn, UCSF, ImmunityBio, Northwest Bio, and multiple Chinese centers.
Combination and delivery approaches — Tumor Treating Fields (TTFields/Optune), focused ultrasound BBB opening, convection-enhanced delivery, and multi-modal combination regimens.
Key targets reviewed
The article includes a table of major tumor-associated antigens under investigation — EGFRvIII, IL13Rα2, GD2, B7-H3, EphA2, HER2, CD70, and CD133 — with prevalence data and therapeutic rationale for each.
Clinical data
The article includes an efficacy scorecard organizing treatments by strength of evidence, from therapies with reproducible survival benefits to those with promising but unconfirmed signals to those that have failed in late-stage trials. These assessments reflect the author's interpretation of available data as of the article's publication date. The GBM treatment landscape is evolving rapidly and some information may have changed since publication.
Five-year outlook
The article concludes with the author's assessment of likely near-term developments through 2030, the treatments he considers most likely to reach approval, the role of Chinese biotech in the global pipeline, and trends in investment in advanced cell and gene therapies. These represent the author's opinions as an investor and should be read in that context.
The full article includes eight comparison tables enabling cross-modality benchmarking of companies, targets, trial stages, and efficacy signals.
Frequently asked questions
What is glioblastoma?
Glioblastoma (GBM) is a Grade 4 brain tumor arising from glial cells. It is characterized by diffuse infiltrative growth, extreme tumor heterogeneity, and an immunosuppressive microenvironment. Median survival with standard treatment is 12 to 15 months.
What treatments are currently approved for glioblastoma?
Current standard of care includes surgical resection, radiation, and temozolomide chemotherapy. Bevacizumab is approved for recurrent GBM. Tumor Treating Fields (Optune) is approved for both newly diagnosed and recurrent GBM. G47Δ (Delytact) received conditional approval in Japan in 2021 for recurrent or residual GBM.
What is CAR-T cell therapy for glioblastoma?
CAR-T cell therapy involves engineering a patient's T cells to express chimeric antigen receptors targeting specific proteins on GBM cells. Clinical trials are evaluating targets including IL13Rα2, EGFRvIII, GD2, HER2, and B7-H3. Intrathecal and intraventricular delivery routes have shown more promising results than intravenous administration in early trials.
What is oncolytic virus therapy for brain cancer?
Oncolytic viruses are engineered to selectively infect and destroy cancer cells while stimulating an immune response against the tumor. G47Δ, a modified herpes simplex virus, received conditional approval in Japan based on Phase 2 data showing 84% one-year survival in recurrent GBM versus approximately 15% in historical controls.
Why has glioblastoma been so difficult to treat?
Key obstacles include the blood-brain barrier limiting drug delivery, extreme intratumoral heterogeneity enabling adaptive resistance, an immunosuppressive tumor microenvironment, and the infiltrative growth pattern making complete surgical resection impossible.
What glioblastoma treatments are in clinical trials?
Active areas of clinical investigation include CAR-T cell therapies targeting multiple antigens, oncolytic virus combinations with checkpoint inhibitors, mRNA neoantigen vaccines, focused ultrasound blood-brain barrier opening, and platform trials such as GBM AGILE evaluating multiple agents simultaneously.
This post is for informational purposes only and does not constitute medical advice.